These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 3432450)

  • 1. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW; Maguire KP; Davies BM
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction between moclobemide and oral tyramine in depressed patients.
    Burgess CD; Mellsop GW
    Fundam Clin Pharmacol; 1989; 3(1):47-52. PubMed ID: 2714732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R; Fischbach R; Breuel HP
    Acta Psychiatr Scand Suppl; 1990; 360():76-7. PubMed ID: 2248082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M; Nardi AE; Figueira IL; Stabl M
    Acta Psychiatr Scand Suppl; 1990; 360():24-8. PubMed ID: 2123366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R
    Acta Psychiatr Scand Suppl; 1990; 360():81-3. PubMed ID: 2248084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers.
    Berlin I; Zimmer R; Cournot A; Payan C; Pedarriosse AM; Puech AJ
    Clin Pharmacol Ther; 1989 Sep; 46(3):344-51. PubMed ID: 2673623
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Moclobemide].
    Gleiter C; Volz HP
    Dtsch Med Wochenschr; 1995 Aug; 120(34-35):1175-6. PubMed ID: 7656852
    [No Abstract]   [Full Text] [Related]  

  • 8. A risk-benefit assessment of moclobemide in the treatment of depressive disorders.
    Norman TR; Burrows GD
    Drug Saf; 1995 Jan; 12(1):46-54. PubMed ID: 7741983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Moclobemide (Ro 11-1163) versus tranylcypromine in the treatment of endogenous depression.
    Gabelic I; Kuhn B
    Acta Psychiatr Scand Suppl; 1990; 360():63. PubMed ID: 2248076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyramine pressor sensitivity in healthy subjects during combined treatment with moclobemide and selegiline.
    Korn A; Wagner B; Moritz E; Dingemanse J
    Eur J Clin Pharmacol; 1996; 49(4):273-8. PubMed ID: 8857072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Moclobemide. An update of its pharmacological properties and therapeutic use.
    Fulton B; Benfield P
    Drugs; 1996 Sep; 52(3):450-74. PubMed ID: 8875133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monoamine oxidase inhibitors in psychiatry. Status of current knowledge].
    Volz HP; Gleiter CH; Möller HJ
    Nervenarzt; 1996 May; 67(5):339-47. PubMed ID: 9005342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of reversible inhibitors of monoamine oxidase-A in various forms of depression.
    Lecrubier Y; Guelfi JD
    Acta Psychiatr Scand Suppl; 1990; 360():18-23. PubMed ID: 2248063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RIMA--a new concept in the treatment of depression with moclobemide.
    Amrein R; Hetzel W; Stabl M; Schmid-Burgk W
    Int Clin Psychopharmacol; 1993 Jan; 7(3-4):123-32. PubMed ID: 8468432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An Australian multicentre study of moclobemide versus amitriptyline in the treatment of depression.
    Evans L; George T; O'Sullivan B; Mitchell P; Johnson G; Adena M
    Aust N Z J Psychiatry; 1992 Sep; 26(3):454-8. PubMed ID: 1417632
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Moclobemide versus tranylcypromine in the treatment of depression.
    Rossel L; Moll E
    Acta Psychiatr Scand Suppl; 1990; 360():61-2. PubMed ID: 2248075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tyramine pharmacodynamics during combined administration of lazabemide and moclobemide.
    Dingemanse J; Hussain Y; Korn A
    Int J Clin Pharmacol Ther; 1996 Apr; 34(4):172-7. PubMed ID: 8861736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Moclobemide, a new reversible MAO inhibitor--interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients.
    Korn A; Eichler HG; Fischbach R; Gasic S
    Psychopharmacology (Berl); 1986; 88(2):153-7. PubMed ID: 3081926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switch in treatment from tricyclic antidepressants to moclobemide: a new generation monoamine oxidase inhibitor.
    Dingemanse J; Kneer J; Fotteler B; Groen H; Peeters PA; Jonkman JH
    J Clin Psychopharmacol; 1995 Feb; 15(1):41-8. PubMed ID: 7714227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers.
    Audebert C; Blin O; Monjanel-Mouterde S; Auquier P; Pedarriosse AM; Dingemanse J; Durand A; Cano JP
    Eur J Clin Pharmacol; 1992; 43(5):507-12. PubMed ID: 1483487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.